The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.
Journal of Affective Disorders March 1, 2025 Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al. 35 citations
To determine the relationships between psilocybin dose, psychedelic experiences, and therapeutic outcome in treatment-resistant depression. For treatment-resistant depression, 233 participants received a single dose of 25, 10, or 1 mg of COMP360 psilocybin (a proprietary, pharmaceutical-grade synthesized psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.) with...
DOI: 10.1016/j.jad.2024.12.061 (opens in new tab)
Full text (opens in new tab)
Magic mushrooms
Treatment-resistant depression
Psychedelics psilocybin
Hallucinogens
+8